neuroprotection

Purinergic Receptor Systems in Microglia: Therapeutic Targets for Neuroprotection.. The open drug discovery journal. 2010-01-01, 2: 148–167. PMID 21961028

受體激動劑，而血清素和褪黑激素並沒有此種機制。 以"TrkB受體"為介導(TrkB-mediated)而產生出強勁的抗抑鬱，神經保護(neuroprotection)和神经营养因子等效果。 此外，光線照射抑制NAS的合成、和減少單胺氧化抑製劑的抗抑鬱作用。 這些數據強烈支持NAS在調節情緒和引起抗抑鬱藥的治療效益之作用。

Purinergic Receptor Systems in Microglia: Therapeutic Targets for Neuroprotection.. The open drug discovery journal. 2010-01-01, 2: 148–167. PMID 21961028

Rationale And Ongoing Status In A Phase 3 Trial Of Nelonemdaz, A Novel Neuroprotection Drug, For Patients With Acute Ischemic Stroke And Reperfusion. Stroke

West Sussex, England, 2009; p 230-232. Defeudis FV. Bilobalide and neuroprotection. Pharmacological Research. 2002, 46 (6): 565–8. PMID 12457632. doi:10